PDF(Pubmed)
Abstract：
Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson\'s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.
摘要：
药物的重新定位和重新利用已被证明有助于确定许多疾病的新疗法，然后可以迅速进入临床实践。目前,除了胆碱酯酶抑制剂外，很少有有效的药物治疗路易体痴呆（包括路易体痴呆和帕金森病痴呆）。我们回顾了几种有希望的化合物，这些化合物可能是路易体痴呆的疾病修饰剂，然后进行了国际德尔菲共识研究，以优先考虑化合物。我们确定氨溴索是排名最高的再利用药物，并从酪氨酸激酶抑制剂类别中确定了另外六种药物。GLP-1受体激动剂,和血管紧张素受体阻滞剂，被我们的专家小组的大多数评为证明临床试验是合理的。现在将所有这些化合物推进路易体痴呆的II期或III期临床试验是及时的。
